Plays an important role in transactivating viral early genes as well as activating its own promoter. Targets and disrupts host PML/nuclear domain 10 (ND10). Promotes efficient viral growth by interacting with and directing host SP100 to degradation, leading to enhanced acetylation level of histones. In addition, functions in counteracting the host innate antiviral response. Inhibits the type I interferon pathway by directly interacting with and sequestrating host STAT2. Alters host cell cycle progression, probably through its interaction with host E2F1 or RB1 that overcomes the RB1-mediated repression of E2F-responsive promoters.
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Epitope||HLA||Vector Type||Inquiry & Datasheet|
|TCR-C102Z||Human anti-IE-1 T cell receptor, pCDTCR1||CMV||Human||ELRRKMMYM||HLA-B8||Lentiviral|
|CAT||Product Name||Clone||Promotor||Packaging System||Targeting Diseases||Inquiry & Datasheet|
|VP-TCR-C201||Lenti-IE-1 T cell receptor Viral Particle||CMV||Lentivirus|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE